- Home
- DRD vs DNTH Comparison
DRD vs DNTH Comparison
Compare DRD & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRD
- DNTH
- Stock Information
- Founded
- DRD 1895
- DNTH 2015
- Country
- DRD South Africa
- DNTH United States
- Employees
- DRD N/A
- DNTH N/A
- Industry
- DRD Precious Metals
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- DRD Basic Materials
- DNTH Health Care
- Exchange
- DRD Nasdaq
- DNTH Nasdaq
- Market Cap
- DRD 792.6M
- DNTH 711.2M
- IPO Year
- DRD N/A
- DNTH N/A
- Fundamental
- Price
- DRD $8.81
- DNTH $23.80
- Analyst Decision
- DRD Strong Buy
- DNTH Strong Buy
- Analyst Count
- DRD 1
- DNTH 9
- Target Price
- DRD $13.25
- DNTH $46.43
- AVG Volume (30 Days)
- DRD 224.6K
- DNTH 203.1K
- Earning Date
- DRD 01-01-0001
- DNTH 11-07-2024
- Dividend Yield
- DRD 2.49%
- DNTH N/A
- EPS Growth
- DRD 3.58
- DNTH N/A
- EPS
- DRD 0.84
- DNTH N/A
- Revenue
- DRD $341,805,849.00
- DNTH $5,366,000.00
- Revenue This Year
- DRD $20.95
- DNTH $98.73
- Revenue Next Year
- DRD N/A
- DNTH N/A
- P/E Ratio
- DRD $10.45
- DNTH N/A
- Revenue Growth
- DRD 13.53
- DNTH 51.41
- 52 Week Low
- DRD $6.48
- DNTH $8.24
- 52 Week High
- DRD $12.70
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- DRD 36.83
- DNTH 46.14
- Support Level
- DRD $8.66
- DNTH $22.59
- Resistance Level
- DRD $10.20
- DNTH $24.57
- Average True Range (ATR)
- DRD 0.34
- DNTH 1.49
- MACD
- DRD -0.05
- DNTH 0.04
- Stochastic Oscillator
- DRD 9.74
- DNTH 30.84
About DRD DRDGOLD Limited
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields; and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.